Nevada Execution in Doubt After Drug Company Sues to Stop it
(LAS VEGAS) — A pharmaceutical company urged a judge to block the use of one of its drugs to execute a two-time killer Wednesday night, saying the state of Nevada obtained the product through “subterfuge” for unapproved purposes.
Alvogen’s objections — aired at a hearing that unfolded less than 11 hours before Scott Raymond Dozier was to be put to death with a three-drug injection never before tried in the U.S. — threatened to put the execution on hold.
Todd Bice, an attorney with New Jersey-based Alvogen, accused the state of deceptively obtaining the company’s drug by having it shipped to a pharmacy in Las Vegas rather than the state prison in Ely. Alvogen sent a letter to state officials in April telling them it opposes the use of its products in executions, particularly the sedative midazolam, Bice said.
A second pharmaceutical company, Sandoz, also raised objections Wednesday to the use of one of its drugs — the muscle-paralyzing substance cisatracurium — in the execution. But the company did not immediately ask to formally join Alvogen’s lawsuit.
A third company, Pfizer, last year demanded Nevada return the third drug intended for use in the execution, the powerful opioid fentanyl. But the state has refused. Fentanyl, which has been blamed for deadly overdoses across the country, has not been used before in an execution.
Jordan T. Smith, an assistant Nevada solicitor general, countered at Wednesday’s hearing that Nevada didn’t put up a “smokescreen” or do anything wrong in getting the drugs. He said drugs ordered by the state prison system are regularly shipped to Las Vegas.
“This whole action is just PR damage control,” Smith said of Alvogen.
Pharmaceutical companies have resisted the use of their drugs in executions for 10 years, citing both legal and ethical concerns. However, the legal challenge filed by Alvogen is only the second of its kind in the U.S, said Robert Dunham, executive director of the Death Penalty Information Center in Washington. The previous challenge, filed last year by a different company in Arkansas, was unsuccessful in halting that execution.
Alvogen’s midazolam was substituted in May for Nevada’s expired stock of diazepam, commonly known as Valium. Nevada’s new execution protocol also calls for the use of fentanyl to slow the inmate’s breathing and cisatracurium to stop his breathing.
Dozier, who attempted suicide in the past, has said he prefers execution to life behind bars.
“Life in prison isn’t a life,” the 47-year-old Army veteran and methamphetamine user and dealer told the Las Vegas Review-Journal recently. In court hearings and letters, he said there is a limit to how much artwork and exercise a person can do in prison.
Dozier was sentenced to death in 2007 for robbing, killing and dismembering 22-year-old Jeremiah Miller at a Las Vegas motel in 2002. Miller had come to Nevada to buy ingredients to make meth. His decapitated torso was found in a suitcase.
In 2005, Dozier was sentenced to 22 years in prison for shooting to death another drug-trade associate, 26-year-old Jasen Greene, whose body was found in 2002 in a shallow grave outside Phoenix. A witness testified Dozier used a sledgehammer to break Greene’s limbs so the corpse would fit in a plastic storage container.
Though Dozier dropped attempts to save his own life, he allowed federal public defenders to challenge the execution protocol. They argued that the untried three-drug combination would be less humane than putting down a pet.
Midazolam has been used with inconsistent results in states including Alabama, Arkansas, Arizona, Florida and Ohio. In 2014, an inmate in Ohio and another one in Arizona were left gasping and snorting before they died in what death penalty foes called botched executions.
Nevada’s last execution was in 2006.
___
Associated Press writers Lindsay Whitehurst and Julian Hattem in Salt Lake City contributed to this report.
